TY - JOUR
T1 - Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate
AU - Brennen, W. Nathaniel
AU - Zhang, Baohui
AU - Kulac, Ibrahim
AU - Kisteman, L. Nelleke
AU - Antony, Lizamma
AU - Wang, Hao
AU - Meeker, Alan K.
AU - De Marzo, Angelo M.
AU - Garraway, Isla P.
AU - Denmeade, Samuel R.
AU - Isaacs, John T.
N1 - Publisher Copyright:
© Brennen et al.
PY - 2017
Y1 - 2017
N2 - Mesenchymal Stem Cells (MSCs) have been identified in prostate cancer, raising the critical question of their physical and temporal source. Therefore, MSCs were quantified and characterized in benign and malignant prostate tissue representing different disease states and a wide range of age groups from fetal development through adult death using analytical and functional methodologies. In contrast to lineage-restricted Mesenchymal Progenitor Cells (MPCs) found in normal prostate tissue, MSCs with tri-lineage differentiation potential (adipogenesis, osteogenesis, and chondrogenesis) are identified in prostate tissue from a subset of men with prostate cancer, consistent with an influx of more stem-like progenitors (i.e. MSCs) from the bone marrow. Additionally, prostate tissue from a subset of these patients is highly enriched in MSCs, suggesting their enumeration may have prognostic value for identifying men with aggressive disease. This influx is an ongoing process continuing throughout disease progression as documented by the presence of MSCs in metastatic lesions from multiple organ sites harvested at the time of death in metastatic castration-resistant prostate cancer (mCRPC) patients. This infiltration of MSCs from systemic circulation provides the rationale for their use as a cell-based vector to deliver therapeutic agents.
AB - Mesenchymal Stem Cells (MSCs) have been identified in prostate cancer, raising the critical question of their physical and temporal source. Therefore, MSCs were quantified and characterized in benign and malignant prostate tissue representing different disease states and a wide range of age groups from fetal development through adult death using analytical and functional methodologies. In contrast to lineage-restricted Mesenchymal Progenitor Cells (MPCs) found in normal prostate tissue, MSCs with tri-lineage differentiation potential (adipogenesis, osteogenesis, and chondrogenesis) are identified in prostate tissue from a subset of men with prostate cancer, consistent with an influx of more stem-like progenitors (i.e. MSCs) from the bone marrow. Additionally, prostate tissue from a subset of these patients is highly enriched in MSCs, suggesting their enumeration may have prognostic value for identifying men with aggressive disease. This influx is an ongoing process continuing throughout disease progression as documented by the presence of MSCs in metastatic lesions from multiple organ sites harvested at the time of death in metastatic castration-resistant prostate cancer (mCRPC) patients. This infiltration of MSCs from systemic circulation provides the rationale for their use as a cell-based vector to deliver therapeutic agents.
KW - Benign prostatic hyperplasia
KW - Mesenchymal stem cells
KW - Prostate cancer
KW - Stem/progenitor cell
KW - Tissue-specific stem cell
UR - http://www.scopus.com/inward/record.url?scp=85024371111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024371111&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.17362
DO - 10.18632/oncotarget.17362
M3 - Article
C2 - 28493842
AN - SCOPUS:85024371111
SN - 1949-2553
VL - 8
SP - 46710
EP - 46727
JO - Oncotarget
JF - Oncotarget
IS - 29
ER -